theranostics
(5)
MIM makes medical scans earn their keep
A scan can reveal a great deal and still leave a clinician with hours of work. MIM built a business in that awkward gap - and GE HealthCare bought it for a reported $283 million purchase price.
Alpha-9 Oncology
Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Holobeam Technologies
Holobeam Technologies is a Bethpage, New York biotech developing Holographic Energy Teleportation (HET), a patented method of focusing energy to precise microscopic locations inside the body. Paired with antibody-guided AdvaNan nanoparticles, the approach - branded the Holothermia protocol - aims to both detect individual cancer cells earlier than conventional imaging and heat them to death while sparing surrounding tissue. Founded by prolific inventor Gene Dolgoff, the LCD-projector pioneer who says he conceived the Star Trek Holodeck, the company is building HET-based MRI and portable scanners for diagnosis and treatment.
AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies (TAT) for cancer, powered by its proprietary Lead-212 (212Pb) alpha isotope generator technology. By solving the chronic supply bottleneck of alpha-emitting isotopes, AdvanCell aims to deliver highly potent, tumor-specific radiation that destroys cancer cells while sparing healthy tissue. Its lead asset, ADVC001, a 212Pb-PSMA therapy, is in clinical trials for metastatic prostate cancer, with a deepening pipeline targeting melanoma, ovarian, breast, and lung cancers.
Ratio Therapeutics
Ratio Therapeutics is a Boston-based clinical-stage biotech engineering next-generation targeted radiopharmaceuticals for solid tumors. Its proprietary Trillium and Macropa platforms tune how radioactive cancer-killing payloads travel through the body, aiming to deliver a lethal dose to tumors while sparing healthy tissue. Backed by major pharma partners including Novartis, Bayer, Lantheus and Bristol Myers Squibb, Ratio is advancing FAP- and SSTR2-targeted programs from imaging into therapy.